Poly-Medics,Inc.
PolyMedics Innovations (PMI) is a pioneering company specializing in synthetic skin technology and biomaterials for wound healing. With over two decades of experience, PMI develops innovative, biodegradable, and biocompatible products such as SUPRATHEL® and SUPRA SDRM®, which are used worldwide to improve wound care, especially for burns and difficult-to-heal wounds. The company is committed to advancing wound treatment through proprietary polylactide technology, clinical research, and sustainable practices, aiming to revolutionize wound healing and enhance patient outcomes globally.
Industries
Nr. of Employees
small (1-50)
Poly-Medics,Inc.
Am Hegelesberg 1, 73230 Kirchheim unter Teck, Germany
Products
Synthetic absorbable epidermal membrane
A single-application, porous synthetic membrane intended as a temporary epidermal substitute for epidermal and dermal wounds and split-thickness skin graft donor sites; formulated from lactide-based copolymers and designed to be hydrolytically biodegradable.
Biodegradable dermal regeneration matrix
A porous biodegradable dermal matrix with combined microporous and larger-pore structure intended for chronic and difficult-to-heal wounds to support granulation and re-epithelialisation.
Silicone-coated contact layer
A one-sided silicone-coated contact layer intended to serve as a contact interface for wounds, applicable alone or in combination with porous polymer membranes or matrices.
Synthetic absorbable epidermal membrane
A single-application, porous synthetic membrane intended as a temporary epidermal substitute for epidermal and dermal wounds and split-thickness skin graft donor sites; formulated from lactide-based copolymers and designed to be hydrolytically biodegradable.
Biodegradable dermal regeneration matrix
A porous biodegradable dermal matrix with combined microporous and larger-pore structure intended for chronic and difficult-to-heal wounds to support granulation and re-epithelialisation.
Silicone-coated contact layer
A one-sided silicone-coated contact layer intended to serve as a contact interface for wounds, applicable alone or in combination with porous polymer membranes or matrices.
Services
Presentations, poster sessions and clinical case dissemination at international conferences to support clinical adoption and training.
Provision and maintenance of Instructions for Use (IFU), SSCPs and other regulatory documentation required for marketed medical devices.
Commercial distribution and market presence across multiple international markets supported by local distributors and sales activities.
Presentations, poster sessions and clinical case dissemination at international conferences to support clinical adoption and training.
Provision and maintenance of Instructions for Use (IFU), SSCPs and other regulatory documentation required for marketed medical devices.
Commercial distribution and market presence across multiple international markets supported by local distributors and sales activities.
Expertise Areas
- Synthetic biomaterials for wound healing
- Dermal matrix and membrane development
- Clinical trial management and outcomes research
- Regulatory compliance for medical devices (CE, FDA 510(k), MDR)
Key Technologies
- Polylactide-based biodegradable polymers
- Porous polymer matrices for tissue regeneration
- Hydrolytic biodegradation to CO2 and H2O
- Biodegradable membrane and dermal matrix design
News & Updates
PMI received the award for its retrospective study demonstrating the efficacy of PLA in wound healing, significantly reducing healing time and improving outcomes.
A case where SUPRATHEL® helped treat Stevens-Johnson Syndrome, supporting skin regeneration and recovery in a pediatric patient.
PMI and Grupo Vuelo showcased SUPRATHEL® at the Mexican Burn Conference, highlighting its role in burn management.
PMI presented case studies on the application of Polylactide (PLA) in treating various wounds and burns at the European Wound Management Association conference.
Recognition for the efficacy of PLA in treating diabetic foot ulcers and venous leg ulcers, demonstrating faster healing and higher closure rates.
A collection of publications supporting the efficacy and mechanisms of PLA-based wound healing products like SUPRATHEL® and SUPRA SDRM®.
PMI received the award for its retrospective study demonstrating the efficacy of PLA in wound healing, significantly reducing healing time and improving outcomes.
A case where SUPRATHEL® helped treat Stevens-Johnson Syndrome, supporting skin regeneration and recovery in a pediatric patient.
PMI and Grupo Vuelo showcased SUPRATHEL® at the Mexican Burn Conference, highlighting its role in burn management.
PMI presented case studies on the application of Polylactide (PLA) in treating various wounds and burns at the European Wound Management Association conference.
Recognition for the efficacy of PLA in treating diabetic foot ulcers and venous leg ulcers, demonstrating faster healing and higher closure rates.
A collection of publications supporting the efficacy and mechanisms of PLA-based wound healing products like SUPRATHEL® and SUPRA SDRM®.